Abstract
BackgroundAromatase Inhibitors (AI) are an important component in adjuvant therapy in postmenopausal women with positive estrogenic receptors in breast cancer. They inhibit the enzyme Cytochrome P450 CYP19, which causes a...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have